BiotechTube
Hone Bio

Hone Bio

London, United Kingdom· Est.
hone.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Hone Bio is a VC-backed, pre-clinical biotech tackling a fundamental limitation in lipid nanoparticle (LNP) drug delivery: inherent liver accumulation. The company's proprietary NanoPilot technology is a membrane-anchored antibody platform that actively blocks liver uptake while simultaneously directing LNPs to desired target cells via a modular targeting domain. This dual-function technology, which can be applied to standard LNPs in a simple 10-minute process, has the potential to expand the therapeutic application of mRNA, DNA, and other nucleic acid payloads to treat diseases in tissues like the lungs, brain, and immune cells. Hone Bio is part of the Science Creates ecosystem in Bristol and is advancing its platform through preclinical validation.

OncologyGenetic DiseasesInfectious DiseaseAutoimmune/Inflammatory

Technology Platform

NanoPilot: An antibody-based fusion protein platform that coats standard lipid nanoparticles (LNPs) to actively block ApoE-mediated liver uptake and provide modular, cell-specific targeting for extrahepatic drug delivery.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The technology addresses the major bottleneck in LNP therapeutics—liver tropism—unlocking a vast market for nucleic acid drugs targeting extrahepatic tissues like immune cells, lungs, and solid tumors.
The simple, modular platform is highly attractive for partnerships, enabling rapid co-development with biopharma companies seeking to target their payloads.
The application for in vivo CAR-T generation represents a particularly high-value opportunity to disrupt a costly and complex therapeutic modality.

Risk Factors

The platform is at a pre-clinical stage, with unproven safety and efficacy in humans.
Significant scientific risk remains in translating promising animal data to clinical success.
The company operates in a fiercely competitive landscape with well-funded rivals exploring alternative targeting technologies.
As a pre-revenue, VC-backed startup, it faces financial runway risks and dependence on successful future fundraising or partnership deals.

Competitive Landscape

Hone Bio competes in the rapidly evolving field of targeted non-viral delivery, facing competition from both large biopharma (e.g., Moderna, BioNTech, AstraZeneca) and numerous biotech startups (e.g., ReCode Therapeutics, Entos Pharmaceuticals, Vesigen Therapeutics) developing their own targeting ligands, conjugates, or novel lipid formulations. Differentiation hinges on NanoPilot's unique dual mechanism of active blocking and targeting, and its simple, post-formulation coating process.

More companies in United Kingdom →